REGN: Regeneron Pharmaceuticals Inc. Stocks News on August 3, 2025

REGN

StockStory

3 days ago

Regeneron (REGN) Q2 Earnings: What To Expect

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

REGN

GlobeNewswire

4 days ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates

REGN

Zacks

4 days ago

Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates

REGN

Zacks

4 days ago

Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

REGN

Zacks

5 days ago

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

REGN

Insider Monkey

6 days ago

Canaccord Reiterates a Buy Rating on Regeneron Pharmaceuticals (REGN)

2 Healthcare Stocks That Are Losing to the S&P 500 This Year

REGN

Motley Fool

6 days ago

2 Healthcare Stocks That Are Losing to the S&P 500 This Year

REGN

Insider Monkey

10 days ago

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

REGN

Insider Monkey

10 days ago

Longleaf Partners Fund Increased its Holdings in Regeneron Pharmaceuticals (REGN) on a Dip

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation

REGN

GlobeNewswire

10 days ago

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation

3 Low-Volatility Stocks We Steer Clear Of

REGN

StockStory

10 days ago

3 Low-Volatility Stocks We Steer Clear Of

TOP SCIENCE TEACHERS ANNOUNCED FOR 12TH ANNUAL REGENERON STEM TEACHING FELLOWSHIP

REGN

PR Newswire

10 days ago

TOP SCIENCE TEACHERS ANNOUNCED FOR 12TH ANNUAL REGENERON STEM TEACHING FELLOWSHIP

Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances

REGN

GlobeNewswire

11 days ago

Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances

AstraZeneca Plans to Invest $50 Billion in U.S. by 2030

REGN

The Wall Street Journal

12 days ago

AstraZeneca Plans to Invest $50 Billion in U.S. by 2030

Health Canada extends Evkeeza approval for children with HoFH

REGN

Pharmaceutical Technology

19 days ago

Health Canada extends Evkeeza approval for children with HoFH

1 Healthcare Stock on Our Buy List and 2 to Brush Off

REGN

StockStory

19 days ago

1 Healthcare Stock on Our Buy List and 2 to Brush Off

Ascites Market Analysis and Forecasts Report 2025-2035 | Market Surges Amid Rising Liver Disease and Cancer Prevalence

REGN

GlobeNewswire

20 days ago

Ascites Market Analysis and Forecasts Report 2025-2035 | Market Surges Amid Rising Liver Disease and Cancer Prevalence

Myopic Macular Degeneration Market Analysis and Forecast Report 2025-2035 | Advancements in Anti-VEGF Therapies Driving Progress in Treatments

REGN

GlobeNewswire

20 days ago

Myopic Macular Degeneration Market Analysis and Forecast Report 2025-2035 | Advancements in Anti-VEGF Therapies Driving Progress in Treatments

Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape

REGN

GlobeNewswire

20 days ago

Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape

REGN

MT Newswires

22 days ago

UBS Raises Price Target on Regeneron Pharmaceuticals to $584 From $560, Keeps Neutral Rating

REGN

Insider Monkey

23 days ago

Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target

Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights

REGN

GlobeNewswire

23 days ago

Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights

REGN

MT Newswires

23 days ago

Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $754 From $755, Maintains Overweight Rating

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

REGN

Business Wire

24 days ago

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

Regeneron’s Blockbuster Dupixent Faces a New Rival

REGN

Barrons.com

25 days ago

Regeneron’s Blockbuster Dupixent Faces a New Rival

The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

REGN

Barchart

25 days ago

The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

Regeneron’s Lynozyfic Gains Accelerated FDA Approval for Multiple Myeloma

REGN

Insider Monkey

a month ago

Regeneron’s Lynozyfic Gains Accelerated FDA Approval for Multiple Myeloma

Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.

REGN

Investor's Business Daily

a month ago

Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

REGN

CNW Group

a month ago

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Intellia Gains 29.8% in a Month: How Should You Play the Stock?

REGN

Zacks

a month ago

Intellia Gains 29.8% in a Month: How Should You Play the Stock?

REGN

MT Newswires

a month ago

RBC Raises Price Target on Regeneron Pharmaceuticals to $688 From $662, Keeps Sector Perform Rating

REGN

Motley Fool

a month ago

2 Beaten-Down Stocks to Buy and Hold

FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

REGN

Zacks

a month ago

FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma

REGN

Pharmaceutical Technology

a month ago

Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma

REGN

Insider Monkey

a month ago

Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA

Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment

REGN

The Wall Street Journal

a month ago

Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment

$Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma$

REGN

GlobeNewswire

a month ago

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

REGN

Zacks

a month ago

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

REGN

Morningstar Research

a month ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind

REGN

Investor's Business Daily

a month ago

Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind

Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million

REGN

Associated Press Finance

a month ago

Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million

REGN

Simply Wall St.

a month ago

Regeneron Pharmaceuticals (NasdaqGS:REGN) Exits Multiple Russell Growth Indices

Former 23andMe CEO regains company control as $305m sale to nonprofit approved

REGN

Medical Device Network

a month ago

Former 23andMe CEO regains company control as $305m sale to nonprofit approved

Circle initiated, Disney upgraded: Wall Street's top analyst calls

REGN

The Fly

a month ago

Circle initiated, Disney upgraded: Wall Street's top analyst calls

REGN

MT Newswires

a month ago

Argus Research Downgrades Regeneron Pharmaceuticals to Hold From Buy

REGN

Argus Research

a month ago

Analyst Report: Regeneron Phars, Inc

REGN

Argus Research

a month ago

Market Digest: REGN

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

REGN

GlobeNewswire

a month ago

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

Regeneron Launches $200 Million Donation Matching Program to Support Vision Care

REGN

Insider Monkey

a month ago

Regeneron Launches $200 Million Donation Matching Program to Support Vision Care

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

REGN

Zacks

a month ago

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?

REGN

Zacks

a month ago

Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

REGN

GlobeNewswire

a month ago

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

REGN

Insider Monkey

a month ago

UBS Lowers Price Target On Regeneron Pharmaceuticals, Inc. (REGN).

The Top 5 Analyst Questions From Regeneron’s Q1 Earnings Call

REGN

StockStory

a month ago

The Top 5 Analyst Questions From Regeneron’s Q1 Earnings Call

REGN

StockStory

a month ago

Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks

The Score: 23andMe, U.S. Steel, Accenture and More Stocks That Defined the Week

REGN

The Wall Street Journal

a month ago

The Score: 23andMe, U.S. Steel, Accenture and More Stocks That Defined the Week

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

REGN

Reuters

a month ago

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

From $6B Valuation to Bankruptcy to Rescue: Wojcicki Reclaims 23andMe for $305M

REGN

Benzinga

a month ago

From $6B Valuation to Bankruptcy to Rescue: Wojcicki Reclaims 23andMe for $305M

Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid

REGN

Zacks

a month ago

Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid

REGN

MT Newswires

a month ago

Sector Update: Health Care

REGN

MT Newswires

a month ago

Regeneron, Sanofi Say US FDA Approves Dupixent for Rare Skin Condition Disease

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

REGN

GlobeNewswire

a month ago

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

REGN

Simply Wall St.

a month ago

Shareholders Approve Bylaw Amendments at Regeneron Pharmaceuticals (NasdaqGS:REGN) Annual Meeting

REGN

Insider Monkey

a month ago

Regeneron Pharmaceuticals, Inc. (REGN) Growth Story Shifts as Wells Fargo Maintains Hold

Celltrion opens new UK headquarters in Uxbridge, UK

REGN

Business Wire

a month ago

Celltrion opens new UK headquarters in Uxbridge, UK

REGN

MT Newswires

2 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

REGN

MT Newswires

2 months ago

Update: Regeneron Pharmaceuticals Opts Out From Raising Offer for 23andMe

Anne Wojcicki wins bid to buy back 23andMe for $305M

REGN

MedTech Dive

2 months ago

Anne Wojcicki wins bid to buy back 23andMe for $305M

REGN

MT Newswires

2 months ago

Market Chatter: Regeneron Pharmaceuticals Opts Out From Raising Offer for 23andMe

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction

REGN

BioPharma Dive

2 months ago

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction

Anne Wojcicki's bid to buy back 23andMe may not end legal fight over DNA customer data

REGN

Yahoo Finance

2 months ago

Anne Wojcicki's bid to buy back 23andMe may not end legal fight over DNA customer data

Anne Wojcicki's bid to buy back 23andMe may not end a legal fight over DNA customer data

REGN

Yahoo Finance

2 months ago

Anne Wojcicki's bid to buy back 23andMe may not end a legal fight over DNA customer data

Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer

REGN

Reuters

2 months ago

Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer

EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM

REGN

Pharmaceutical Technology

2 months ago

EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM

REGN

MT Newswires

2 months ago

Regeneron Pharmaceuticals Loses Bid as 23andMe to Sell Core Assets to TTAM for $305 Million

REGN

MT Newswires

2 months ago

Sanofi, Regeneron Say Dupixent Outperforms Xolair in Phase 4 Respiratory Trial

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

REGN

GlobeNewswire

2 months ago

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025

REGN

Motley Fool

2 months ago

These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025

REGN

The Wall Street Journal

2 months ago

Anne Wojcicki Wins Bidding for 23andMe

23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm

REGN

Reuters

2 months ago

23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm

23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process

REGN

GlobeNewswire

2 months ago

23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process

These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025

REGN

Motley Fool

2 months ago

These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025

Consumer sentiment, Regeneron meeting, Apple WWDC: What to Watch

REGN

Yahoo Finance Video

2 months ago

Consumer sentiment, Regeneron meeting, Apple WWDC: What to Watch

Dozens of states sue to block the sale of 23andMe’s genetic data after its former CEO pushes the purchase price $50 million higher

REGN

Fortune

2 months ago

Dozens of states sue to block the sale of 23andMe’s genetic data after its former CEO pushes the purchase price $50 million higher

Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?

REGN

Motley Fool

2 months ago

Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?

REGN

Insider Monkey

2 months ago

JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target

23andMe says 15% of customers asked to delete their genetic data since bankruptcy

REGN

TechCrunch

2 months ago

23andMe says 15% of customers asked to delete their genetic data since bankruptcy

REGN

Zacks

2 months ago

Stock Market News for Jun 10, 2025

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season

REGN

Benzinga

2 months ago

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season

Regeneron and Sanofi’s dupilumab shows promise in AD trial

REGN

Clinical Trials Arena

2 months ago

Regeneron and Sanofi’s dupilumab shows promise in AD trial

As tech leads, which stocks have outperformed since April 8 rout?

REGN

Yahoo Finance Video

2 months ago

As tech leads, which stocks have outperformed since April 8 rout?

REGN

MT Newswires

2 months ago

JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $800 From $950, Maintains Overweight Rating

REGN

MT Newswires

2 months ago

Regeneron, Sanofi Say Atopic Dermatitis Trial Shows Improvement in Disease Severity

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

REGN

GlobeNewswire

2 months ago

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

REGN

Insider Monkey

2 months ago

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?

REGN

Zacks

2 months ago

Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?

Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial

REGN

Barrons.com

2 months ago

Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial

The New Twist In Regeneron's 23andMe Bankruptcy Buyout

REGN

Investor's Business Daily

2 months ago

The New Twist In Regeneron's 23andMe Bankruptcy Buyout

REGN

MT Newswires

2 months ago

UBS Adjusts Regeneron Pharmaceuticals Price Target to $560 From $633, Maintains Neutral Rating

REGN

Zacks

2 months ago

Latest Regeneron Pharmaceuticals Inc. (REGN) News on August 3, 2025

Share on Social Networks: